Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly

8 Sept 2017

Abstract excerpt

PURPOSE: Despite availability of multimodal treatment options for acromegaly, achievement of long-term disease control is suboptimal in a significant number of patients. Furthermore, disease control as defined by biochemical normalization may not always show concordance with disease-related symptoms or patient's perceived quality of life. We developed and validated a tool to measure disease activity in acromegaly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Growth Hormone and Insulin-like Growth Factors
Share to Myasthenia Gravis and Thymoma
Share to Pituitary Gland Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28887782
DOI: 10.1007/s11102-017-0835-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegalyPMID 28887782Read ↗

Consensus on acromegaly complications: an updateSemantic proximity Read ↗

Growth Hormone Assay-Adjusted Standardization Reveals Distinct Clinical Phenotypes in Acromegaly.Semantic proximity Read ↗

Treatment of acromegaly in the era of personalized and predictive medicine.Semantic proximity Read ↗

Standards of Care for Medical Management of Acromegaly in Pituitary Tumor Centers of Excellence (PTCOE)Semantic proximity Read ↗

Efficacy and Safety of Pasireotide Treatment in Acromegaly: A Systematic Review and Single Arm Meta-AnalysisSemantic proximity Read ↗

Clinical and radiographic assessment of peripheral joints in controlled acromegalySemantic proximity Read ↗

[Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición].Semantic proximity Read ↗

Multidimensional Geriatric Evaluation in Acromegaly: A Comparative Cross-Sectional StudySemantic proximity Read ↗

Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotypeSemantic proximity Read ↗

Acromegaly: unravelling a complex disease.Semantic proximity Read ↗

The knowledge and attitudes of primary care physicians about acromegaly: a survey study with multinational participationSemantic proximity Read ↗

Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.